These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29749386)

  • 21. Bacteriocins as alternative agents for control of multiresistant staphylococcal strains.
    Nascimento JS; Ceotto H; Nascimento SB; Giambiagi-Demarval M; Santos KR; Bastos MC
    Lett Appl Microbiol; 2006 Mar; 42(3):215-21. PubMed ID: 16478507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Formicin - a novel broad-spectrum two-component lantibiotic produced by Bacillus paralicheniformis APC 1576.
    Collins FWJ; O'Connor PM; O'Sullivan O; Rea MC; Hill C; Ross RP
    Microbiology (Reading); 2016 Sep; 162(9):1662-1671. PubMed ID: 27450592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and characterization of a bioactive lantibiotic produced by Staphylococcus warneri.
    Petersen J; Boysen A; Fogh L; Tabermann K; Kofoed T; King A; Schrotz-King P; Hansen MC
    Biol Chem; 2009; 390(5-6):437-44. PubMed ID: 19361283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Lantibiotics, a class of ribosomally synthesized peptide antibiotics].
    Entian KD; Klein C
    Naturwissenschaften; 1993 Oct; 80(10):454-60. PubMed ID: 8264800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of lantibiotic gallidermin against biogenic amine-producing faecal staphylococci from ostriches and pheasants.
    Lauková A; Kandričáková A; Pleva P; Buňková L; Ščerbová J
    Folia Microbiol (Praha); 2017 May; 62(3):229-235. PubMed ID: 28084600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineering of a novel thioether bridge and role of modified residues in the lantibiotic Pep5.
    Bierbaum G; Szekat C; Josten M; Heidrich C; Kempter C; Jung G; Sahl HG
    Appl Environ Microbiol; 1996 Feb; 62(2):385-92. PubMed ID: 8593044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pseudomycoicidin, a Class II Lantibiotic from Bacillus pseudomycoides.
    Basi-Chipalu S; Dischinger J; Josten M; Szekat C; Zweynert A; Sahl HG; Bierbaum G
    Appl Environ Microbiol; 2015 May; 81(10):3419-29. PubMed ID: 25769830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lantibiotic immunity.
    Draper LA; Ross RP; Hill C; Cotter PD
    Curr Protein Pept Sci; 2008 Feb; 9(1):39-49. PubMed ID: 18336322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insights into in vivo activities of lantibiotics from gallidermin and epidermin mode-of-action studies.
    Bonelli RR; Schneider T; Sahl HG; Wiedemann I
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1449-57. PubMed ID: 16569864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of Lantibiotic Salivaricins: New Weapons to Fight Infectious Diseases.
    Barbour A; Wescombe P; Smith L
    Trends Microbiol; 2020 Jul; 28(7):578-593. PubMed ID: 32544444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Highly efficient Staphylococcus carnosus mutant selection system based on suicidal bacteriocin activation.
    Krismer B; Nega M; Thumm G; Götz F; Peschel A
    Appl Environ Microbiol; 2012 Feb; 78(4):1148-56. PubMed ID: 22179253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Production of bacteriocins by coagulase-negative staphylococci involved in bovine mastitis.
    dos Santos Nascimento J; Fagundes PC; de Paiva Brito MA; dos Santos KR; do Carmo de Freire Bastos M
    Vet Microbiol; 2005 Mar; 106(1-2):61-71. PubMed ID: 15737474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolation and structural characterization of epilancin 15X, a novel lantibiotic from a clinical strain of Staphylococcus epidermidis.
    Ekkelenkamp MB; Hanssen M; Danny Hsu ST; de Jong A; Milatovic D; Verhoef J; van Nuland NA
    FEBS Lett; 2005 Mar; 579(9):1917-22. PubMed ID: 15792796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a high cell-density protocol for the production of pregallidermin, a non-toxic precursor of the lantibiotic gallidermin.
    Medaglia G; Valsesia G; Panke S
    J Biotechnol; 2010 Jan; 145(2):176-85. PubMed ID: 19932136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lantibiotic production by pathogenic microorganisms.
    Daly KM; Cotter PD; Hill C; Ross RP
    Curr Protein Pept Sci; 2012 Sep; 13(6):509-23. PubMed ID: 22708496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural and functional diversity of lantibiotic immunity proteins.
    Okuda K; Sonomoto K
    Curr Pharm Biotechnol; 2011 Aug; 12(8):1231-9. PubMed ID: 21470153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of staphylococcal bacteriocins against Staphylococcus aureus and Streptococcus agalactiae involved in bovine mastitis.
    Varella Coelho ML; Santos Nascimento JD; Fagundes PC; Madureira DJ; Oliveira SS; Vasconcelos de Paiva Brito MA; Freire Bastos Mdo C
    Res Microbiol; 2007 Sep; 158(7):625-30. PubMed ID: 17719749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mass spectroscopic analysis of a novel enzymatic reaction. Oxidative decarboxylation of the lantibiotic precursor peptide EpiA catalyzed by the flavoprotein EpiD.
    Kupke T; Kempter C; Gnau V; Jung G; Götz F
    J Biol Chem; 1994 Feb; 269(8):5653-9. PubMed ID: 8119901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biosynthesis of the antimicrobial peptide epilancin 15X and its N-terminal lactate.
    Velásquez JE; Zhang X; van der Donk WA
    Chem Biol; 2011 Jul; 18(7):857-67. PubMed ID: 21802007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a fermentation process based on a defined medium for the production of pregallidermin, a nontoxic precursor of the lantibiotic gallidermin.
    Medaglia G; Panke S
    Appl Microbiol Biotechnol; 2010 Jun; 87(1):145-57. PubMed ID: 20213184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.